Initiate the pivotal clinical trial for OLC
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 23 Oct 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We expect to initiate the pivotal trial for OLC before the end of this year”
What we found
Evidence strength A What the grades mean
The company successfully initiated the pivotal clinical trial for OLC in December 2023, meeting its commitment to start the trial before the end of that year.
-
A Unicycive Therapeutics, Inc. 10-K filed 2025-03-31
“This study was initiated in December 2023” ✓ confirmed on the page
Market reaction: the shares moved -12.2% against the S&P 500 over the three sessions around the disclosure (28 Mar 2025 to 2 Apr 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- pivotal clinical trial for OLC
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-UNCY-002791 · Corrections policy